Cutting-edge nanotechnology is now emerging, with strong clinical evidence, as an alternative to amorphous solid dispersion (ASD), able to not only address bioavailability challenges but also deliver higher drug loads in much more patient friendly formats with fewer and smaller pills and easier regimens.
Our downloadable content is temporarily unavailable due to a website update. If you’re interested in any of our content pieces during this time, please contact us at info@nanoform.com.